Volume 12 Supplement 1

Statins in cardiometabolic disease: what makes pitavastatin different?


Edited by Enrique Fisman and Alexander Tenenbaum

Publication of this supplement has been funded by Kowa Pharmaceutical Europe. Pitavastatin is a product marketed by the sponsor of the supplement. Articles are based on the proceedings of the World Congress for the Prevention of Diabetes. Authors received support with the preparation of their articles from GK Pharmacomm, an agency funded by the sponsor. All articles have undergone the journal's standard peer review process. The Supplement Editors declare that they have no competing interests.

Statins in cardiometabolic disease: what makes pitavastatin different?.

Madrid, Spain

11-14 November 2012

  1. Proceedings

    Pitavastatin in cardiometabolic disease: therapeutic profile

    Statins effectively lower low-density lipoprotein-cholesterol (LDL-C) and reduce cardiovascular risk in people with dyslipidemia and cardiometabolic diseases such as Metabolic syndrome (MetS) or type 2 diabete...

    Luis Masana

    Cardiovascular Diabetology 2013 12(Suppl 1):S2

    Published on: 30 May 2013

  2. Proceedings

    Statin diabetogenicity: guidance for clinicians

    Type 2 diabetes (T2D) is a strong, independent risk factor for cardiovascular (CV) and cerebrovascular outcomes. Meta-analysis of five randomised clinical trials (n = 33,040) showed that, although intensive versu...

    Kausik Ray

    Cardiovascular Diabetology 2013 12(Suppl 1):S3

    Published on: 30 May 2013